

Integrating Diagnostics and Therapeutics for Targeted Therapies, Part 2: The Importance of Calculating the Return on Investment

Peter Keeling, M.B.A.

Diaceutics

Table of Contents

Introduction	2
Reasons for Calculating the Return on Investment	2
Estimates of Return	3
Using Case-Based Reasoning to Calculate the Return on Investment	5
The Diaceutics Model	5
Variables	5
Analyzing Scenarios Using Case-Based Reasoning	7
Hypothesis 1: A Related Diagnostic Will Accelerate the Uptake of a Novel Drug in Clinical Areas Where Diagnosis Is Difficult	7
Hypothesis 2: A Related Monitoring Test Will Improve Patient Compliance with a Drug That Requires Long-Term Use	7
Hypothesis 3: A Well-Managed Diagnostic Program Can Justify Premium Pricing, Offsetting Restrictions in the Size of the Patient Pool	9
Evaluating a Diagnostic Partnership	10

In This Issue...

As the promise of diagnostic/therapeutic combinations is increasingly recognized, pharmaceutical companies must determine best practices in terms of comarketing these combinations. This two-part series is designed to showcase fundamental considerations in diagnostic/drug comarketing plans. Part 1 of this series examined the potential benefit that drug companies can gain from entering into well-planned marketing collaborations with diagnostics companies and presented a framework on which to build these collaborations. In Part 2, we focus on the importance of the financial justification for those collaborations. To highlight the importance of this analysis, we discuss the variables that must be considered when quantifying the expected return. We review three hypotheses often encountered when determining the benefit of a diagnostic, applying to them historical cases in which the relationships between diagnosis and treatment can be measured or analyzed and used as benchmarks when estimating the financial return on new ventures.